Does Ocrevus reduce disability progression? Examining the evidence
•
3 min read
Over 2.8 million people worldwide are affected by Multiple Sclerosis (MS), a chronic disease where a central treatment goal is to slow or prevent disability progression. For many with the condition, a key question is: **Does Ocrevus reduce disability progression**? Evidence from major clinical trials and over a decade of follow-up demonstrates that this B-cell targeting therapy has a significant and sustained effect in delaying disability worsening in both relapsing and primary progressive forms of the disease.
